References
- McGill JB Sloan L Newman J Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study Diabetes Care 2013 36 2 237 244 23033241
- United States Renal Data System USRDS 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States 2012 Available from: http://www.usrds.org/atlas.aspx Accessed July 16, 2013
- White SL Chadban SJ Jan S Chapman JR Cass A How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ 2008 86 3 229 237 18368211
- United States Renal Data System USRDS 2009 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States 2009 Available from: http://www.usrds.org/atlas09.aspx Accessed July 16, 2013
- de Boer IH Rue TC Hall YN Heagerty PJ Weiss NS Himmelfarb J Temporal trends in the prevalence of diabetic kidney disease in the United States JAMA 2011 305 24 2532 2539 21693741
- National Kidney Foundation USRDS 2010 annual data report: kidney disease by the numbers 2010 Available from: http://www.kidney.org/advocacy/pdf/KIDNEY_DISEASE_BY_THE_NUMBERS.pdf Accessed July 16, 2013
- Heidemann C Boeing H Pischon T Nothlings U Joost HG Schulze MB Association of a diabetes risk score with risk of myocardial infarction, stroke, specific types of cancer, and mortality: a prospective study in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort Eur J Epidemiol 2009 24 6 281 288 19357973
- International Diabetes Federation Diabetes Atlas 5th ed 2012 Available from: http://www.idf.org/diabetesatlas/5e/the-global-burden Accessed July 16, 2013
- Skyler JS Bergenstal R Bonow RO Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Circulation 2009 119 2 351 357 19095622
- Boehringer Ingelheim Pharmaceuticals Inc Tradjenta (linagliptin) tablets prescribing information 2011 (updated 2013 June). Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Tradjenta/Tradjenta.pdf Accessed July 16, 2013
- Arjona Ferreira JC Marre M Barzilai N Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency Diabetes Care 2013 36 5 1067 1073 23248197
- Arjona Ferreira JC Corry D Mogensen CE Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial Am J Kidney Dis 2013 61 4 579 587 23352379
- Kothny W Shao Q Groop PH Lukashevich V One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment Diabetes Obes Metab 2012 14 11 1032 1039 22690943
- Nowicki M Rychlik I Haller H Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study Int J Clin Pract 2011 65 12 1230 1239 21977965